207 related articles for article (PubMed ID: 20735432)
1. Programmed cell death 4 enhances chemosensitivity of ovarian cancer cells by activating death receptor pathway in vitro and in vivo.
Zhang X; Wang X; Song X; Liu C; Shi Y; Wang Y; Afonja O; Ma C; Chen YH; Zhang L
Cancer Sci; 2010 Oct; 101(10):2163-70. PubMed ID: 20735432
[TBL] [Abstract][Full Text] [Related]
2. PDCD4 inhibits the malignant phenotype of ovarian cancer cells.
Wei ZT; Zhang X; Wang XY; Gao F; Zhou CJ; Zhu FL; Wang Q; Gao Q; Ma CH; Sun WS; Fu QZ; Chen YH; Zhang LN
Cancer Sci; 2009 Aug; 100(8):1408-13. PubMed ID: 19493270
[TBL] [Abstract][Full Text] [Related]
3. Programmed cell death 4 (PDCD4) mediates the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by down-regulation of FLIP expression.
Wang W; Zhao J; Wang H; Sun Y; Peng Z; Zhou G; Fan L; Wang X; Yang S; Wang R; Fang D
Exp Cell Res; 2010 Sep; 316(15):2456-64. PubMed ID: 20595005
[TBL] [Abstract][Full Text] [Related]
4. Bcl-X(L) is functionally non-equivalent for the regulation of growth and survival in human ovarian cancer cells.
Dodier P; Piché A
Gynecol Oncol; 2006 Feb; 100(2):254-63. PubMed ID: 16188300
[TBL] [Abstract][Full Text] [Related]
5. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
7. Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis.
Afonja O; Juste D; Das S; Matsuhashi S; Samuels HH
Oncogene; 2004 Oct; 23(49):8135-45. PubMed ID: 15361828
[TBL] [Abstract][Full Text] [Related]
8. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
9. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
[TBL] [Abstract][Full Text] [Related]
10. Protoapigenone, a novel flavonoid, inhibits ovarian cancer cell growth in vitro and in vivo.
Chang HL; Su JH; Yeh YT; Lee YC; Chen HM; Wu YC; Yuan SS
Cancer Lett; 2008 Aug; 267(1):85-95. PubMed ID: 18430509
[TBL] [Abstract][Full Text] [Related]
11. Pro-apoptotic treatment with an adenovirus encoding Bax enhances the effect of chemotherapy in ovarian cancer.
Xiang J; Gómez-Navarro J; Arafat W; Liu B; Barker SD; Alvarez RD; Siegal GP; Curiel DT
J Gene Med; 2000; 2(2):97-106. PubMed ID: 10809143
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.
Henkels KM; Turchi JJ
Cancer Res; 1999 Jul; 59(13):3077-83. PubMed ID: 10397248
[TBL] [Abstract][Full Text] [Related]
13. [Relationship between expression of apoptosis-associated proteins and caspase-3 activity in cisplatin-resistant human ovarian cancer cell line].
Yang XK; Zheng F; Chen JH; Gao QL; Lu YP; Wang SX; Wang CY; Ma D
Ai Zheng; 2002 Dec; 21(12):1288-91. PubMed ID: 12520732
[TBL] [Abstract][Full Text] [Related]
14. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
Puca R; Nardinocchi L; Pistritto G; D'Orazi G
Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
[TBL] [Abstract][Full Text] [Related]
16. Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro.
Leong CT; Ong CK; Tay SK; Huynh H
Oncogene; 2007 Feb; 26(6):870-80. PubMed ID: 16862170
[TBL] [Abstract][Full Text] [Related]
17. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas.
Herr I; Ucur E; Herzer K; Okouoyo S; Ridder R; Krammer PH; von Knebel Doeberitz M; Debatin KM
Cancer Res; 2003 Jun; 63(12):3112-20. PubMed ID: 12810637
[TBL] [Abstract][Full Text] [Related]
18. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
19. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
Wang Y; Niu XL; Qu Y; Wu J; Zhu YQ; Sun WJ; Li LZ
Cancer Lett; 2010 Sep; 295(1):110-23. PubMed ID: 20236757
[TBL] [Abstract][Full Text] [Related]
20. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin.
Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X
Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]